Medical degradable magnesium alloy composite coating, method for preparing coating, composite material with coating, electrolyte and application of electrolyte
By preparing the HA-NrGO-1.5CS composite coating on the surface of the magnesium alloy, the problems of high corrosion rate and corrosion by-product accumulation of magnesium alloy in the human body are solved, significantly improving its corrosion resistance and promoting the bone healing process.
Patent Information
- Application Number
- CN202411175768.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
AI Technical Summary
The high corrosion rate of magnesium alloy in the human physiological system leads to insufficient tissue healing, the accumulation of corrosion by-products causes inflammation and tissue damage, and the accumulation of hydrogen leads to local pH increase, reducing its application value in orthopedic implantation.
Stainless steel is used as the anode and magnesium alloy is used as the cathode. The coating is prepared by electrophoretic deposition and thermal reduction technology to form HA-NrGO-1.5CS Triple composite coating improves corrosion resistance of magnesium alloys.
The corrosion resistance of magnesium alloys is significantly improved in simulated body fluids, delay the path of corrosion ions to the substrate surface, generate an apatite layer and MgO2 protective film, prevent the binding of amine groups to H2O molecules, reduce the corrosion rate, and promote bone tissue proliferation.
Smart Images

Figure CN119061452A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedical degradable magnesium-based material coating surfaces, and specifically relates to a medical degradable magnesium alloy composite coating and a method for preparing the coating, a composite material with a coating, an electrolyte and applications thereof. Background Art
[0002] Magnesium and its alloys have attracted much attention due to their excellent biodegradability and biocompatibility, and are considered as potential human orthopedic implant materials. Their elastic modulus and compressive yield strength are close to those of natural bone, which helps to reduce stress shielding. Magnesium-based alloys corrode naturally under physiological conditions, avoiding secondary surgery after bone healing, and their corrosion products Mg 2+ It is harmless to the human body and can be discharged safely.
[0003] The biggest limitation of biodegradable magnesium alloys as orthopedic implants is that the high corrosion rate of magnesium alloys in the human physiological system causes the tissue to lose its mechanical integrity before it fully heals, and leads to the harmful accumulation of corrosion byproducts. The large amount of hydrogen accumulation produced by the corrosion of Mg will increase the local pH of the human body, thereby causing local inflammation and tissue damage. Therefore, the unmodified magnesium alloy matrix has low corrosion resistance in human body fluids and cannot be used. Summary of the invention
[0004] The present invention provides a medical degradable magnesium alloy composite coating and a method for preparing the coating, a composite material with a coating, an electrolyte and applications thereof, aiming to modify the magnesium alloy to improve the corrosion resistance of the magnesium alloy, thereby reducing the degree of corrosion of the implanted magnesium alloy stent and allowing the bone at the wound to heal perfectly.
[0005] The technical problem to be solved by the present invention is achieved by adopting the following technical solutions:
[0006] A method for preparing a coating on the surface of a medical degradable magnesium alloy, wherein stainless steel is used as an anode, a magnesium alloy having a MgF2 conversion layer on the surface is used as a cathode, a ternary composite material suspension is used as an electrolyte, electrophoresis is performed to deposit the coating on the cathode surface, and then thermal reduction is performed to obtain the coating;
[0007] Wherein: the ternary composite material suspension contains graphene oxide, hydroxyapatite, chitosan and solvent; the mass ratio of graphene oxide, hydroxyapatite and chitosan is 1:1-2:1-2, and the ratio of the mass of graphene oxide to the total volume of the solvent is 0.1-0.5 mg / mL.
[0008] Preferably, the mass ratio of graphene oxide, hydroxyapatite and chitosan is 1:2:1.5, and the ratio of the mass of graphene oxide to the total volume of the solvent is 0.1-0.4 mg / mL.
[0009] Preferably, the electrophoretic deposition conditions are: deposition voltage of 110V-150V, deposition for 1-5min, and drying at 25-35°C for 12-36h;
[0010] The thermal reduction conditions are: in an argon environment, the heating rate is 1-10°C / min, the room temperature is raised to 100-300°C, and the temperature is kept at 100-300°C for 1-2h.
[0011] Furthermore, the electrophoretic deposition conditions are as follows: deposition voltage is 140 V, deposition is 3 min, and drying is performed at 30° C. for 24 h;
[0012] The thermal reduction conditions are as follows: in an argon environment, the heating rate is 5°C / min, the room temperature is raised to 200°C, and the temperature is kept at 200°C for 2h.
[0013] Preferably, the solvent includes deionized water, anhydrous ethanol and acetic acid, and the volume ratio of the deionized water, anhydrous ethanol and acetic acid is: 1:1-4:0.001-0.01.
[0014] Furthermore, the volume ratio of deionized water, anhydrous ethanol and acetic acid is 1:4:0.005.
[0015] Preferably, the ternary composite material suspension further contains AlCl3, and the mass ratio of the graphene oxide to AlCl3 is 1:2-3.
[0016] Furthermore, the mass ratio of the graphene oxide to AlCl3 is 2:5.
[0017] A medical degradable magnesium alloy with a composite coating on the surface is prepared by the preparation method described above.
[0018] An electrolyte for preparing a medical degradable magnesium alloy surface coating, the electrolyte containing a ternary composite material suspension, the ternary composite material suspension containing graphene oxide, hydroxyapatite, chitosan and a solvent; the mass ratio of the graphene oxide, hydroxyapatite and chitosan is 1:1-2:1-2, and the ratio of the mass of the graphene oxide to the total volume of the solvent is 0.1-0.5 mg / mL.
[0019] Preferably, the mass ratio of graphene oxide, hydroxyapatite and chitosan is 1:2:1.5, and the ratio of the mass of graphene oxide to the total volume of the solvent is 0.3-0.5 mg / mL.
[0020] Preferably, the ternary composite material suspension further contains AlCl3, and the mass ratio of the graphene oxide to AlCl3 is 1:2-3.
[0021] Furthermore, the mass ratio of the graphene oxide to AlCl3 is 2:5.
[0022] The electrolyte described above is used to prepare a medical degradable magnesium alloy surface coating.
[0023] The beneficial effects of the present invention are:
[0024] (1) The present invention adds hydroxyapatite, graphene oxide, and chitosan to a mixed solution of anhydrous ethanol, deionized water, and acetic acid to prepare a suspension, and then uses the suspension to prepare a coating intermediate using an electrophoretic deposition technique, and then obtains a ternary composite coating through heat treatment, and has excellent corrosion resistance, wherein the expression is that the HA-NrGO-1.5CS ternary composite coating has the best corrosion resistance.
[0025] (2) The ternary composite coating has very ideal corrosion resistance after being immersed in simulated body fluid (SBF) for 30 min and 2 days. Among them, the apatite layer generated in the early stage of immersion in SBF fills the cracks and pits, effectively delaying the path of corrosion ions reaching the substrate surface. With the increase of immersion time, CS acts as a N source, and the addition of N atoms in the rGO lattice can increase the activity of oxygen reduction reaction and induce the formation of OOH. - Intermediate.
[0026] (3) In neutral electrolytes (such as simulated body fluid SBF), OOH - Intermediate and H + The amount of MgO2 generated by the combination of H2O2 and MgO2 increases with the increase of H2O2 content and the decrease of pH value. In the early stage of immersion in SBF solution, Mg 2+ Combined with H2O2 to form MgO2, it provides a passivation / protective film for the ZK60 magnesium alloy substrate. In the corrosion mechanism of the ternary composite coating, the negatively charged phosphate ions (HPO4 2- and H2PO 4- ) can interact electrostatically with the protonated amine groups on CS, thereby preventing the amine groups from binding to H2O molecules.
[0027] (4) In addition, the protonation of the -NH2 group in CS (-NH2 is converted to -NH 3+ ) hinders Cl - and OH - The ions reach the surface of ZK60Mg alloy, thereby hindering the corrosion of ZK60 Mg alloy.
[0028] (5) The improvement of corrosion resistance is the result of the combined effect of the apatite layer and the corrosion product MgO2. Similarly, the generated MgO2 can promote the proliferation of bone tissue, and the generation of MgO2 is also a process of uniform corrosion on the surface of Mg alloy. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1Potential polarization curves of the uncoated sample (Comparative Example 1) and HA-NrGO-CS coated samples with different CS contents (Examples 1-3) after immersion in simulated body fluid (SBF) for 30 minutes (a) and 2 days (b);
[0030] Figure 2 Electrochemical impedance spectroscopy (EIS) of the uncoated sample (Comparative Example 1) and HA-NrGO-CS coated samples with different CS contents (Examples 1-3) after immersion in simulated body fluid (SBF) for 30 minutes (a) and 2 days (b).
[0031] Figure 3 (a), (b), and (c) are scanning electron microscope (SEM) images of the interfaces of the composite coatings of Examples 1, 2, and 3, respectively.
[0032] Figure 4 (a) is a scanning electron microscope image of the coating sample of Example 1 (HA-NrGO-1.0CS) of the present invention immersed in simulated body fluid (SBF) for two days; Figure 4 (b) Figure 4 Elemental mapping of C, N, O, Ca, P, and Mg in (a); Figure 4 (C) Figure 4 Count the elements in (b).
[0033] Figure 5 (a) is a scanning electron microscope image of the coating sample of Example 2 (HA-NrGO-1.5CS) of the present invention immersed in simulated body fluid (SBF) for two days; Figure 5 (b) Figure 5 Elemental mapping of C, N, O, Ca, P, and Mg in (a); Figure 5 (C) Figure 5 Count the elements in (b).
[0034] Figure 6 (a) is a scanning electron microscope image of the coating sample of Example 3 (HA-NrGO-2.0CS) of the present invention immersed in simulated body fluid (SBF) for two days; Figure 6 (b) Figure 6 Elemental mapping of C, N, O, Ca, P, and Mg in (a); Figure 6 (C) Figure 6 Count the elements in (b).
[0035] Figure 7 Scanning electron microscope surface images of HA-NrGO-CS composite coatings: (a) HA-NrGO-1.0CS, (b) HA-NrGO-1.5CS, (c) HA-NrGO-2.0CS; (b1) Figure 7 The element mapping of C, O, N, Ca, P and Al in (b) and (b2) are Figure 7 (b1) Element content. DETAILED DESCRIPTION
[0036] In order to make the technical means, creative features, objectives and effects of the present invention easier to understand, the present invention is further described below with reference to specific illustrations.
[0037] It should be noted that the present invention requires the following definitions:
[0038] Chemical symbols Chemical name Chemical symbols Chemical name ZK60 magnesium alloy Matrix CS Chitosan SBF solution Human simulated body fluid HA Hydroxyapatite GO Graphene oxide NbGO Nitrogen doped reduced graphene oxide
[0039] In the above table, 1 mL of SBF solution contains 8.035 g of sodium chloride (NaCl), 0.225 g of potassium chloride (KCl), 0.292 g of calcium chloride (CaCl2), 0.311 g of magnesium chloride (MgCl2·6H2O), 0.355 g of sodium bicarbonate (NaHCO3), 0.231 g of dipotassium hydrogen phosphate trihydrate (K2HPO4·3H2O), 0.072 g of sodium sulfate (Na2SO4), and 6.118 g of tris(hydroxymethyl)aminomethane (Tris). The pH value of the solution is adjusted to about 7.25-7.45 with 1 mol / L hydrochloric acid solution to make it close to the pH value of human blood.
[0040] Before preparing the coating on the surface of the medical degradable magnesium alloy (i.e., carrying out the following embodiments and comparative examples), the substrate needs to be pre-treated and pre-treated. The specific process is as follows:
[0041] S1: Pretreatment of the substrate: ZK60 magnesium alloy is processed through grinding, washing and drying processes;
[0042] Specifically,
[0043] The ZK60 magnesium alloy was polished with 180#, 240#, 400#, 800#, 1200#, and 1500# SiC sandpaper, then ultrasonically washed with deionized water for 20 to 40 minutes, and finally dried in a vacuum drying oven at 60°C for later use;
[0044] S2: Pretreatment of the substrate: After the substrate is pretreated in step S1, it is sequentially subjected to alkali washing, acid washing and activation steps to form a MgF2 conversion layer on the surface of the ZK60 magnesium alloy.
[0045] Specifically,
[0046] S2.1 Prepare alkaline treatment solution: mix 1.5g Na3PO4 (30g / L), 2g Na2CO3 (40g / L), and 4g NaOH (80g / L), add deionized water to 50mL, and prepare alkaline treatment solution; acid treatment solution: mix 15mL H3PO4 (300mL / L) and 5mL HF (100mL / L), add deionized water to 50mL, and prepare acid treatment solution; activation treatment solution: mix 5g (NH4HF2 (100g / L) and 10mL H3PO4 (200mL / L), add deionized water to 50mL, and prepare activation treatment solution.
[0047] S2.2 The ZK60 magnesium alloy pre-treated in step S1 is sequentially subjected to alkali washing, acid washing and activation steps; wherein: the alkali washing is performed at 70° C. for 20 minutes to remove surface impurities;
[0048] After alkaline washing, the samples were ultrasonically cleaned with deionized water and then acid washed to remove the surface oxide layer;
[0049] The samples after pickling also need to be ultrasonically cleaned with deionized water; finally, activation treatment is carried out, Mg(OH)2 reacts with HF to form a MgF2 conversion layer on the surface of ZK60 magnesium alloy. The purpose is to act as a transition layer in the electrophoretic deposition process, which can enhance the bonding force between the substrate and the coating.
[0050] Example 1
[0051] A method for preparing a coating on the surface of a medical degradable magnesium alloy is prepared according to the following steps:
[0052] Step 1: Add graphene oxide, hydroxyapatite and chitosan in a ratio of 20 mg: 40 mg: 20 mg to 40 mL of anhydrous ethanol, then add 10 mL of deionized water and 0.05 mL of acetic acid, and finally add 50 mg of AlCl3, and perform ultrasonic stirring for 1 h to obtain a uniformly dispersed suspension for use;
[0053] Step 2: Prepare the HA-GO-1.0CS ternary composite coating on the surface of the pretreated Mg alloy by cathode electrophoretic deposition, with stainless steel as the anode and the Mg alloy with a MgF2 conversion layer on the surface as the cathode. The two electrodes are placed in parallel in the suspension prepared in step 1 with a spacing of 2 cm; deposit for 3 minutes at a voltage of 140 V, and dry the prepared coating in a drying oven at 30° C. for 24 hours to obtain a composite coating intermediate;
[0054] Step 3: Place the dried composite coating intermediate in a tubular furnace under an argon atmosphere for thermal reduction, set the heating rate to 5°C / min, increase the temperature from room temperature to 200°C, and keep it at 200°C for 2h to achieve effective N atom doping and GO reduction, and finally obtain the HA-NrGO-1.0CS ternary composite coating.
[0055] Example 2
[0056] This embodiment is basically the same as Embodiment 1, except that the mass ratio of graphene oxide, hydroxyapatite and chitosan in this embodiment is 20 mg:40 mg:30 mg; and the final ternary composite coating is HA-NrGO-1.5CS.
[0057] Example 3
[0058] This embodiment is basically the same as Embodiment 1, except that the mass ratio of graphene oxide, hydroxyapatite and chitosan in this embodiment is 20 mg:40 mg:40 mg; the final ternary composite coating is HA-NrGO-2.0CS.
[0059] Comparative Example 1
[0060] The ZK60 magnesium alloy used in this comparative example is uncoated.
[0061] test
[0062] In order to verify the corrosion resistance of the present invention, the above-mentioned Examples 1-3 and Comparative Example 1 were subjected to simulated body fluid (SBF) immersion test, electrochemical impedance spectroscopy, polarization test, and scanning electron microscopy (SEM) characterization test.
[0063] 1. Simulated body fluid (SBF) immersion test
[0064] The magnesium alloy sheets with coatings in the above-mentioned Examples 1-3 and the magnesium alloy sheets without coatings in Comparative Example 1 were packaged and coated with metallographic tape, and the exposed area was 1 cm 2 The immersion test was carried out at room temperature, and the simulated body fluid was replaced every 8 hours, and the samples were immersed for 30 minutes and 2 days respectively. The samples after immersion were placed in an oven for drying. After drying, the protective effect of the composite coating on the substrate after immersion was observed, and the corrosion resistance of the coating in the human body environment was evaluated by electrochemical testing.
[0065] 2. Electrochemical test
[0066] The magnesium alloy sheets with coatings in the above-mentioned Examples 1-3 and the magnesium alloy sheets without coatings in Comparative Example 1 were packaged and coated with metallographic tape, and the exposed area was 1 cm 2The immersion experiment was carried out on the area of the sample. The immersion experiment was carried out at room temperature, and the simulated body fluid was replaced every 8 hours, and the samples were immersed for 30 minutes and 2 days respectively. The immersed samples were placed in an oven to dry. After drying, the protective effect of the composite coating on the substrate after immersion was observed, and the corrosion resistance of the coating in the human body environment was evaluated by electrochemical testing. The composite coating was electrochemically tested using a classic three-electrode system electrolytic cell (M005-S), and the composite coating was impedance (EIS) and polarization (Tafel) tested using an Auto lab CHI 650C electrochemical workstation. The platinum electrode was used as the auxiliary electrode, the saturated calomel electrode (SCE) was used as the reference electrode, and the composite coating sample was used as the working electrode. All tests were carried out in SBF solution, and the samples were exposed to 1cm 2 The area of the test is exposed to the corrosive liquid and the measurements are all conducted at room temperature. Figure 1 , Figure 2 , as shown in Table 1.
[0067] The electrochemical data parameters are shown in Table 1, and the corrosion potential E corr and the corrosion current density i corr It is determined by the Tafel extrapolation method. Generally speaking, the greater the corrosion potential, the smaller the corrosion tendency; the smaller the corrosion current density, the smaller the corrosion rate; the higher the polarization resistance, the better the corrosion resistance.
[0068] By Figure 1 (a) It can be seen that compared with the uncoated ZK60 magnesium alloy in Comparative Example 1, the coated ZK60 magnesium alloy in Examples 1-3 has a higher E corr Obviously moving in the positive direction, i corr It moves in the negative direction. According to the principles of thermodynamics and kinetics, it shows that the corrosion resistance of the composite coatings of Examples 1-3 is significantly enhanced. Figure 2 The larger the diameter of the capacitor ring, the stronger the corrosion resistance. Figure 2 As shown in (a), compared with the HA-NrGO-1.0CS and HA-NrGO-2.0CS coating samples after immersion in SBF for 30 min, the capacitance ring diameter of the HA-NrGO-1.5CS composite coating in the Nyquist plot is larger, indicating that it has the best corrosion resistance. In addition, it can be seen from Table 1 that the E corr Maximum (-1.07V), i corr Minimum (11.6uA.cm -2 ), therefore, HA-NrGO-1.5CS has the best corrosion resistance in the composite coating embodiment of the present invention.
[0069] from Figure 1As can be seen from (b) and Table 1, as the immersion time increases from 30 min to 2 days, the E corr The values are obviously increased; by comparing corr It can be found that the i of the ZK60 magnesium alloy with coating in Examples 1-3 after immersion for 2 days is higher than that of the corresponding coated sample after immersion for 30 min. corr The E of HA-NrGO-1.5CS composite coating is significantly reduced, indicating that with the extension of immersion time, the corrosion resistance of ZK60 magnesium alloy with coating in Examples 1-3 is significantly enhanced. corr (-0.29V) maximum, i corr (6.04uA·cm -2 ) is the lowest, indicating that the HA-NrGO-1.5CS composite coating can effectively prevent the corrosion ions from penetrating from the SBF solution into the ZK60 magnesium alloy substrate.
[0070] As the immersion time of the coated ZK60 magnesium alloy in Examples 1-3 of the present invention increases from 30 min to 2 days, the surface porosity of the composite coating is significantly reduced by 3-4 orders of magnitude, confirming the formation of the apatite layer, which is consistent with the polarization results.
[0071] Table 1
[0072]
[0073] 3. Scanning electron microscope (SEM) characterization test
[0074] Under the condition of 3 min deposition time, as the deposition voltage increases, the surface of the HA-NrGO-CS composite coating shows a rough surface. However, the microstructure of the composite coating is slightly different with different deposition voltages. The scanning results are shown in Figure 2. Figure 3 , Figure 4 , Figure 5 , Figure 6 , Figure 7 shown.
[0075] like Figure 3 As shown, compared with the HA-NrGO-1.0CS in Example 1 and the HA-NrGO-2.0CS in Example 3, the HA-NrGO-1.5CS in Example 2 forms a more uniform, dense and thicker coating structure, and there are no pores / cracks on the coating surface, so it has excellent corrosion resistance. The cross-sectional morphology of the HA-NrGO-CS coating sample is shown in Figure 3As shown; it can be clearly observed that the HA-NrGO-CS composite coating has a high adhesion to the ZK60 Mg alloy substrate. Compared with HA-NrGO-1.0CS (Example 1) and HA-NrGO-2.0CS (Example 3), the SEM image of HA-NrGO-1.5CS (Example 2) is the most uniform and dense. The thicknesses of HA-NrGO-1.0CS, HA-NrGO-1.5CS, and HA-NrGO-2.0CS are 52μm, 61μm, and 46μm, respectively.
[0076] Compare the coating before and after immersion, such as Figure 4 , Figure 5 , Figure 6 and Figure 7 As shown in Figure 2, the ZK60 magnesium alloy with coating in Examples 1-3 forms an apatite layer in the SBF solution, which can enhance the corrosion resistance of the ZK60 magnesium alloy matrix. After immersion for 2 days, the porosity of the ZK60 magnesium alloy with coating in Example 2 reaches a minimum of 6.89×10 -6 %, which is consistent with the uniform and dense composite coating results in SEM images (such as Figure 5 As the immersion time increases, the presence of CS, HA, and NrGO in the composite coating can provide Mg 2+ The formation / dissolution of the passive / protective MgO2 film can transform the corrosion behavior of magnesium alloys from pitting corrosion to uniform corrosion. corr Value (6.04uA.cm -2 ) is further reduced and the corrosion resistance is further improved.
[0077] In summary, based on the data from electrochemical impedance spectroscopy, polarization tests, simulated body fluid (SBF) immersion tests, and scanning electron microscopy (SEM) characterization tests, the following conclusions can be drawn:
[0078] The composite coating samples prepared by the present invention can improve the corrosion rate of the substrate in simulated body fluid (SBF), and can effectively improve the corrosion resistance of the substrate. Among them: HA-NrGO-1.5CS (Example 2) has the best corrosion resistance, and the corrosion resistance size relationship is: HA-NrGO-1.5CS>HA-NrGO-2.0CS>HA-NrGO-1.0CS>ZK60 magnesium alloy, that is: Example 2>Example 3>Example 1>Comparative Example 1. Based on the test data analysis and inference of the composite coating (HA-NrGO-1.5CS) in simulated body fluid, its corrosion rate is much lower than that of the magnesium alloy substrate, so that the implanted magnesium alloy stent can slow down the corrosion degree in clinical applications, which is helpful for the healing of bones at the wound.
[0079] A medical degradable magnesium alloy with a composite coating on the surface is prepared by the preparation method described above.
[0080] An electrolyte for preparing a medical degradable magnesium alloy surface coating, the electrolyte containing a ternary composite material suspension, the ternary composite material suspension containing graphene oxide, hydroxyapatite, chitosan and a solvent; the mass ratio of graphene oxide, hydroxyapatite and chitosan is 1:2:1.5, and the ratio of the mass of graphene oxide to the total volume of the solvent is 0.3-0.5 mg / mL.
[0081] The ternary composite material suspension also contains AlCl3, and the mass ratio of graphene oxide to AlCl3 is 2:5.
[0082] The electrolyte described above is used to prepare a medical degradable magnesium alloy surface coating.
[0083] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. Method for preparing coating on the surface of medical degradable magnesium alloy, It is characterized in that Stainless steel is used as the anode, and the surface has MgF 2 The magnesium alloy of the conversion layer is used as the cathode, and the ternary composite material suspension is used as the electrolyte, which is deposited on the cathode surface by electrophoresis and then thermally reduced; Wherein: the ternary composite material suspension contains graphene oxide, hydroxyapatite, chitosan and solvent; the mass ratio of graphene oxide, hydroxyapatite and chitosan is 1:1-2:1-2, and the ratio of the mass of graphene oxide to the total volume of the solvent is 0.1-0.5 mg / mL.
2. The preparation method according to claim 1, It is characterized in that The electrophoretic deposition conditions are as follows: deposition voltage is 110V-150V, deposition time is 1-5min, and drying is performed at 25-35°C for 12-36h; The thermal reduction conditions are: in an argon environment, the heating rate is 1-10°C / min, the room temperature is raised to 100-300°C, and the temperature is kept at 100-300°C for 1-2h.
3. The preparation method according to claim 1, It is characterized in that The solvent includes deionized water, anhydrous ethanol and acetic acid, and the volume ratio of the deionized water, anhydrous ethanol and acetic acid is 1:1-4:0.001-0.
01.
4. The preparation method according to claim 1, It is characterized in that The ternary composite material suspension also contains AlCl 3 , the graphene oxide and AlCl 3 The mass ratio is 1:2-3.
5. A medical degradable magnesium alloy with a composite coating on the surface, It is characterized in that Prepared by the preparation method according to any one of claims 1 to 4.
6. An electrolyte for preparing a medical degradable magnesium alloy surface coating, It is characterized in that The electrolyte contains a ternary composite material suspension, which contains graphene oxide, hydroxyapatite, chitosan and a solvent; the mass ratio of the graphene oxide, hydroxyapatite and chitosan is 1:1-2:1-2, and the ratio of the mass of the graphene oxide to the total volume of the solvent is 0.1-0.5 mg / mL.
7. The electrolyte according to claim 6, It is characterized in that The ternary composite material suspension also contains AlCl 3 , the graphene oxide and AlCl 3 The mass ratio is 1:2-3.
8. The electrolyte according to claim 6 or 7 is used for preparing a medical degradable magnesium alloy surface coating.
